TY - JOUR
AR - COCB-2020-2-102
TI - Proceeding of Glioblastoma Multiforme (GBM): An Advanced Overview
AU - Niraj Kumar, Srivastava
AU - Somnath , Mukherjee
JO - Clinical Oncology and Cancer Biology
PY - 2020
DA - Mon 28, Sep 2020
SN - 2733-2276
DO - http://dx.doi.org/10.31487/j.COCB.2020.02.02
UR - https://www.sciencerepository.org/proceeding-of-glioblastoma-multiforme-gbm-an-advanced-overview_COCB-2020-2-102 
KW - Glioblastoma multiforme, primary brain tumors, high-grade tumor, grade IV tumor, central nervous system tumor, brain cancer
AB - Glioblastoma multiforme (GBM) is a central nervous system tumor of grade IV histological malignancy
according to the WHO classification. GBM is an extraordinary tumor and the worldwide incidence is less
than 10 per 100,000 individuals. The prognosis of this tumor is meagre and survival rate is 15 months
subsequent to diagnosis. Such an atrocious image of this tumor is responsible for a major issue of public
health. This tumor develops from normal glial cells through multistep oncogenesis. Genetic alterations and
deregulations of molecular pathways are responsible for development of both primary and secondary GBM.
Diagnosis of GBM is performed by imaging techniques. These non-invasive imaging techniques are
magnetic resonance imaging (MRI), computed tomography (CT) and Positron emission tomography (PET).
Definitive diagnosis of GBM is based on histopathological examination of the intra operatively removed
tumor or its parts, using traditional histological, cytologic and histochemical methods. NMR (Nuclear
Magnetic Resonance) spectroscopy based possible diagnostic significance of GBM is also reported.
Treatment of glioblastoma multiforme includes tumor resection, as well as radiotherapy and chemotherapy.
Nanomedicine and bacterial protein based therapeutic approaches are in the developmental stage. There is
always need of the development of new therapeutic approaches for GBM to improve the survival and quality
of life.